Literature DB >> 30760888

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.

Michael Platten1,2, Ellen A A Nollen3, Ute F Röhrig4, Francesca Fallarino5, Christiane A Opitz6,7.   

Abstract

L-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp metabolism in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO). However, although small-molecule IDO1 inhibitors showed promise in early-stage cancer immunotherapy clinical trials, a phase III trial was negative. This Review summarizes the physiological and pathophysiological roles of Trp metabolism, highlighting the vast opportunities and challenges for drug development in multiple diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30760888     DOI: 10.1038/s41573-019-0016-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  229 in total

Review 1.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.

Authors:  Jackie E Bader; Kelsey Voss; Jeffrey C Rathmell
Journal:  Mol Cell       Date:  2020-06-18       Impact factor: 17.970

Review 2.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

3.  Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.

Authors:  Christoph Steeneck; Olaf Kinzel; Simon Anderhub; Martin Hornberger; Sheena Pinto; Barbara Morschhaeuser; Floriane Braun; Gerald Kleymann; Thomas Hoffmann
Journal:  ACS Med Chem Lett       Date:  2020-01-27       Impact factor: 4.345

4.  Tryptophan catabolism reflects disease activity in human tuberculosis.

Authors:  Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler
Journal:  JCI Insight       Date:  2020-05-21

5.  Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.

Authors:  Giada Mondanelli; Alice Coletti; Francesco Antonio Greco; Maria Teresa Pallotta; Ciriana Orabona; Alberta Iacono; Maria Laura Belladonna; Elisa Albini; Eleonora Panfili; Francesca Fallarino; Marco Gargaro; Giorgia Manni; Davide Matino; Agostinho Carvalho; Cristina Cunha; Patricia Maciel; Massimiliano Di Filippo; Lorenzo Gaetani; Roberta Bianchi; Carmine Vacca; Ioana Maria Iamandii; Elisa Proietti; Francesca Boscia; Lucio Annunziato; Maikel Peppelenbosch; Paolo Puccetti; Paolo Calabresi; Antonio Macchiarulo; Laura Santambrogio; Claudia Volpi; Ursula Grohmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-05       Impact factor: 11.205

6.  Dopamine is an aryl hydrocarbon receptor agonist.

Authors:  Hyejin Park; Un-Ho Jin; Keshav Karki; Arul Jayaraman; Clint Allred; Sharon K Michelhaugh; Sandeep Mittal; Robert S Chapkin; Stephen Safe
Journal:  Biochem J       Date:  2020-10-16       Impact factor: 3.857

Review 7.  Mechanisms and Implications of Metabolic Heterogeneity in Cancer.

Authors:  Jiyeon Kim; Ralph J DeBerardinis
Journal:  Cell Metab       Date:  2019-09-03       Impact factor: 27.287

8.  Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.

Authors:  Deanna N Edwards; Verra M Ngwa; Ariel L Raybuck; Shan Wang; Yoonha Hwang; Laura C Kim; Sung Hoon Cho; Yeeun Paik; Qingfei Wang; Siyuan Zhang; H Charles Manning; Jeffrey C Rathmell; Rebecca S Cook; Mark R Boothby; Jin Chen
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

9.  Host-microbiome interactions: the aryl hydrocarbon receptor as a critical node in tryptophan metabolites to brain signaling.

Authors:  Ning Ma; Ting He; Lee J Johnston; Xi Ma
Journal:  Gut Microbes       Date:  2020-05-13

10.  Tryptophan metabolism is dysregulated in individuals with Fanconi anemia.

Authors:  Allison L Bartlett; Lindsey Romick-Rosendale; Adam Nelson; Sheyar Abdullah; Nathan Luebbering; Jamen Bartlett; Marion Brusadelli; Joseph S Palumbo; Kelly Lake; Bridget Litts; Alexandra Duell; Annette Urbanski; Adam Lane; Kasiani C Myers; Susanne I Wells; Stella M Davies
Journal:  Blood Adv       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.